Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Carmat to resume first-in-man trial with its bioprosthetic heart


Wednesday, 16 Jul 2014 02:00pm EDT 

Carmat SA:Obtains approval to resume first-in-man trial with its bioprosthetic heart.Patient enrollment put on hold in March to allow data from first implanted prosthesis to be analyzed.Favorable opinion regarding resumption of enrollment of next three patients given by ethics committee, data and safety monitoring board and regulatory authorities. 

Latest Developments for Carmat SA

Company Quote

68.69
0.79 +1.16%
11:35am EST